 At all stages of follow-up, no eyes had lost more than 1 line of best corrected visual acuity (BCVA).
The aim of this retrospective study was to evaluate the medium-term results of Visian ICL (ICH V3) to correct moderate and high hyperopia. (> + 4 D). Endpoints were: efficacy, predictability, stability, safety, intraocular pressure (IOP), vault, endothelial cell count over time, and adverse events. A self-administered questionnaire concerning overall subjective satisfaction with surgery outcomes and post-operative vision was issued at the last follow-up visit. 28 eyes of 15 patients were enrolled in the study, mean follow-up was 3.6 years (range 3 to 6 years), mild to moderate degrees of amblyopia were observed in 15 eyes (54% of eyes). 
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